Trump and AstraZeneca Forge Discount Drug Deal to Lower Medicaid Costs
President Donald Trump announced a discount drug deal with AstraZeneca to reduce Medicaid costs, aiming to lower prescription drug prices in the United States.
- On Friday, President Donald Trump revealed a new agreement with AstraZeneca, allowing the company to sell certain medications at a discount to Medicaid in exchange for tariff relief.
- This deal follows a similar pricing arrangement made with Pfizer last week and represents a strategic move by the White House to tackle high prescription drug costs.
- The agreement with AstraZeneca is part of broader efforts to reform the pharmaceutical industry, potentially impacting millions of Medicaid beneficiaries across the United States.
Why It Matters
This partnership reflects ongoing efforts by the Trump administration to address the rising costs of prescription medications, a critical issue for many Americans. Reducing Medicaid expenses through such deals could have significant implications for healthcare affordability nationwide.